Supplemental Material for: Curative Locoregional Therapy Following Objective Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Le résumé fourni par la source

Introduction: Atezolizumab plus bevacizumab (Atezo-Bev) is a standard first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). We aimed to explore the benefits of adding curative locoregional therapy (LRT) to patients who achieve a partial response to Atezo-Bev treatment. Methods: This multinational retrospective study enrolled patients who received Atezo-Bev as first-line systemic therapy for unresectable HCC and reached complete response (CR) or PR. Patients were categorized into three cohorts: patients who underwent curative LRT after PR, patients with PR but did not receive curative LRT, and patients achieving CR without LRT. Curative LRT included surgery, ablation, and definitive radiotherapy with imaging evidence showing disease-free status afterwards. Results: A total of 243 patients were enrolled from 8 countries or regions; 31 patients received curative LRT after PR, 180 patients obtained PR but did not receive curative LRT, and 32 patients achieved CR without LRT. The curative LRT group, compared with patients who did not receive curative LRT after PR, exhibited significantly longer PFS (median, 44.4 months vs. 18.2 months, p = 0.004) and OS (median, not reached vs. 34.3 months, p < 0.001). The differences remained significant after inverse probability of treatment weighting (IPTW) adjustment. By contrast, whether before or after IPTW adjustment, the curative LRT group did not exhibit statistically significant difference in PFS, OS, and recurrence-free survival from patients who obtained CR without curative LRT. Conclusion: Curative LRT may consolidate the efficacy of Atezo-Bev in patients achieving a partial response, potentially prolonging survival compared to systemic therapy alone.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.